한글목차

개요

포스포디에스테라아제(PDE) 억제제 시장은 2023년부터 2028년에 걸쳐 37억 8,000만 달러 확대되고, 예측 기간 중 연평균 복합 성장률(CAGR)은 6.85%를 나타낼 것으로 예측됩니다.

포스포디에스테라아제(PDE) 억제제 시장에 대한 전체적인 분석, 시장 규모와 예측, 동향, 성장 촉진요인, 과제, 약 25개 벤더를 대상으로 한 벤더 분석 등의 정보를 게재했습니다.

현재의 시장 시나리오, 최신 동향과 촉진요인, 시장 환경 전체에 관한 최신 분석을 제공합니다.이 시장에서는 생활습관 악화, ED의 만연, 차세대 PDE 억제제의 이용 가능성 성장을 가속하고 있습니다.

본 조사에서는 PDE 억제제 개발을 위한 신기술 응용을 향후 몇 년간 포스포디에스테라아제(PDE) 억제제 시장 성장을 가속하는 주요 이유 중 하나라고 보고 있습니다. 또한 노년 인구 증가와 만성질환의 부담 증가는 시장의 높은 수요로 연결될 것입니다.

목차

제1장 주요 요약

• 시장 개요

제2장 시장 구도

• 시장 생태계

제3장 시장 규모

• 시장의 정의
• 시장 부문 분석
• 시장 규모(2023년)
• 시장 전망(2023-2028년)

제4장 시장 규모 실적

• 세계의 포스포디에스테라아제(PDE) 억제제 시장(2018-2022년)
• 용도별 부문 분석(2018-2022년)
• 유형별 부문 분석(2018-2022년)
• 지역별 부문 분석(2018-2022년)
• 국가별 부문 분석(2018-2022년)

제5장 Five Forces 분석

• Five Forces 요약
• 바이어의 교섭력
• 공급 기업의 교섭력
• 신규 진출업체의 위협
• 대체품의 위협
• 경쟁 위협
• 시장 현황

제6장 시장 세분화 : 용도별

• 시장 부문
• 비교 : 용도별
• 경구 : 시장 규모와 예측(2023-2028년)
• 국소 : 시장 규모와 예측(2023-2028년)
• 기타 RoA : 시장 규모와 예측(2023-2028년)
• 시장 기회 : 용도별

제7장 시장 세분화 : 유형별

• 시장 부문
• 비교 : 유형별
• PDE5 억제제 : 시장 규모와 예측(2023-2028년)
• PDE4 억제제 : 시장 규모와 예측(2023-2028년)
• PDE3 및 기타 : 시장 규모와 예측(2023-2028년)
• 시장 기회 : 유형별

제8장 고객 상황

• 고객 상황 개요

제9장 지역별 상황

• 지역별 세분화
• 지역별 비교
• 북미 : 시장 규모와 예측(2023-2028년)
• 유럽 : 시장 규모와 예측(2023-2028년)
• 아시아 : 시장 규모와 예측(2023-2028년)
• 세계 기타 지역 : 시장 규모와 예측(2023-2028년)
• 미국 : 시장 규모와 예측(2023-2028년)
• 독일 : 시장 규모와 예측(2023-2028년)
• 영국 : 시장 규모와 예측(2023-2028년)
• 중국 : 시장 규모와 예측(2023-2028년)
• 프랑스 : 시장 규모와 예측(2023-2028년)
• 시장 기회 : 지역 상황별

제10장 성장 촉진요인, 과제 및 동향

• 시장 성장 촉진요인
• 시장이 해결해야 할 과제
• 성장 촉진요인과 과제의 영향
• 시장 동향

제11장 벤더 구도

• 개요
• 벤더 구도
• 혼란 상황
• 업계 리스크

제12장 벤더 분석

• 대상 벤더
• 벤더의 시장 포지셔닝
• Amgen Inc.
• AstraZeneca Plc
• Bayer AG
• Boehringer Ingelheim International GmbH
• Dong A Socio Holdings Co. Ltd.
• Dr Reddys Laboratories Ltd.
• Eli Lilly and Co.
• GlaxoSmithKline Plc
• Pfizer Inc.
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• United Therapeutics Corp.
• Viatris Inc.
• Zydus Lifesciences Ltd.

제13장 부록

영문목차

Abstract

The phosphodiesterase (PDE) inhibitors market is forecasted to grow by USD 3.78 bn during 2023-2028, accelerating at a CAGR of 6.85% during the forecast period. The report on the phosphodiesterase (PDE) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing adoption of poor lifestyle habits, rising prevalence of ed, and availability of next-generation PDE inhibitors.

Technavio's phosphodiesterase (PDE) inhibitors market is segmented as below:

By Application

• Oral
• Topical
• Other RoA

By Type

• PDE5 inhibitors
• PDE4 inhibitors
• PDE3 and others

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the application of new technologies for PDE inhibitors development as one of the prime reasons driving the phosphodiesterase (PDE) inhibitors market growth during the next few years. Also, growing geriatric population and rising burden of chronic diseases will lead to sizable demand in the market.

The report on the phosphodiesterase (PDE) inhibitors market covers the following areas:

• Phosphodiesterase (PDE) inhibitors market sizing
• Phosphodiesterase (PDE) inhibitors market forecast
• Phosphodiesterase (PDE) inhibitors market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading phosphodiesterase (PDE) inhibitors market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Deciphera Pharmaceuticals Inc, Dong A Socio Holdings Co. Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corp., Viatris Inc., VIVUS LLC, and Zydus Lifesciences Ltd.. Also, the phosphodiesterase (PDE) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Application
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
• Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
• Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global phosphodiesterase (PDE) inhibitors market 2018 - 2022
• Exhibit 18: Historic Market Size - Data Table on global phosphodiesterase (pde) inhibitors market 2018 - 2022 ($ billion)
• 4.2 Application Segment Analysis 2018 - 2022
• Exhibit 19: Historic Market Size - Application Segment 2018 - 2022 ($ billion)
• 4.3 Type Segment Analysis 2018 - 2022
• Exhibit 20: Historic Market Size - Type Segment 2018 - 2022 ($ billion)
• 4.4 Geography Segment Analysis 2018 - 2022
• Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
• 4.5 Country Segment Analysis 2018 - 2022
• Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Application

• 6.1 Market segments
• Exhibit 30: Chart on Application - Market share 2023-2028 (%)
• Exhibit 31: Data Table on Application - Market share 2023-2028 (%)
• 6.2 Comparison by Application
• Exhibit 32: Chart on Comparison by Application
• Exhibit 33: Data Table on Comparison by Application
• 6.3 Oral - Market size and forecast 2023-2028
• Exhibit 34: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
• Exhibit 35: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
• Exhibit 36: Chart on Oral - Year-over-year growth 2023-2028 (%)
• Exhibit 37: Data Table on Oral - Year-over-year growth 2023-2028 (%)
• 6.4 Topical - Market size and forecast 2023-2028
• Exhibit 38: Chart on Topical - Market size and forecast 2023-2028 ($ billion)
• Exhibit 39: Data Table on Topical - Market size and forecast 2023-2028 ($ billion)
• Exhibit 40: Chart on Topical - Year-over-year growth 2023-2028 (%)
• Exhibit 41: Data Table on Topical - Year-over-year growth 2023-2028 (%)
• 6.5 Other RoA - Market size and forecast 2023-2028
• Exhibit 42: Chart on Other RoA - Market size and forecast 2023-2028 ($ billion)
• Exhibit 43: Data Table on Other RoA - Market size and forecast 2023-2028 ($ billion)
• Exhibit 44: Chart on Other RoA - Year-over-year growth 2023-2028 (%)
• Exhibit 45: Data Table on Other RoA - Year-over-year growth 2023-2028 (%)
• 6.6 Market opportunity by Application
• Exhibit 46: Market opportunity by Application ($ billion)
• Exhibit 47: Data Table on Market opportunity by Application ($ billion)

7 Market Segmentation by Type

• 7.1 Market segments
• Exhibit 48: Chart on Type - Market share 2023-2028 (%)
• Exhibit 49: Data Table on Type - Market share 2023-2028 (%)
• 7.2 Comparison by Type
• Exhibit 50: Chart on Comparison by Type
• Exhibit 51: Data Table on Comparison by Type
• 7.3 PDE5 inhibitors - Market size and forecast 2023-2028
• Exhibit 52: Chart on PDE5 inhibitors - Market size and forecast 2023-2028 ($ billion)
• Exhibit 53: Data Table on PDE5 inhibitors - Market size and forecast 2023-2028 ($ billion)
• Exhibit 54: Chart on PDE5 inhibitors - Year-over-year growth 2023-2028 (%)
• Exhibit 55: Data Table on PDE5 inhibitors - Year-over-year growth 2023-2028 (%)
• 7.4 PDE4 inhibitors - Market size and forecast 2023-2028
• Exhibit 56: Chart on PDE4 inhibitors - Market size and forecast 2023-2028 ($ billion)
• Exhibit 57: Data Table on PDE4 inhibitors - Market size and forecast 2023-2028 ($ billion)
• Exhibit 58: Chart on PDE4 inhibitors - Year-over-year growth 2023-2028 (%)
• Exhibit 59: Data Table on PDE4 inhibitors - Year-over-year growth 2023-2028 (%)
• 7.5 PDE3 and others - Market size and forecast 2023-2028
• Exhibit 60: Chart on PDE3 and others - Market size and forecast 2023-2028 ($ billion)
• Exhibit 61: Data Table on PDE3 and others - Market size and forecast 2023-2028 ($ billion)
• Exhibit 62: Chart on PDE3 and others - Year-over-year growth 2023-2028 (%)
• Exhibit 63: Data Table on PDE3 and others - Year-over-year growth 2023-2028 (%)
• 7.6 Market opportunity by Type
• Exhibit 64: Market opportunity by Type ($ billion)
• Exhibit 65: Data Table on Market opportunity by Type ($ billion)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 67: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibit 68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• 9.2 Geographic comparison
• Exhibit 69: Chart on Geographic comparison
• Exhibit 70: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
• Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
• Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.4 Europe - Market size and forecast 2023-2028
• Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
• Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
• Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.5 Asia - Market size and forecast 2023-2028
• Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
• Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
• Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
• Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
• Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 US - Market size and forecast 2023-2028
• Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ billion)
• Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
• Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.8 Germany - Market size and forecast 2023-2028
• Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
• Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
• Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.9 UK - Market size and forecast 2023-2028
• Exhibit 95: Chart on UK - Market size and forecast 2023-2028 ($ billion)
• Exhibit 96: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
• Exhibit 97: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibit 98: Data Table on UK - Year-over-year growth 2023-2028 (%)
• 9.10 China - Market size and forecast 2023-2028
• Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ billion)
• Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ billion)
• Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
• 9.11 France - Market size and forecast 2023-2028
• Exhibit 103: Chart on France - Market size and forecast 2023-2028 ($ billion)
• Exhibit 104: Data Table on France - Market size and forecast 2023-2028 ($ billion)
• Exhibit 105: Chart on France - Year-over-year growth 2023-2028 (%)
• Exhibit 106: Data Table on France - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 107: Market opportunity By Geographical Landscape ($ billion)
• Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 109: Impact of drivers and challenges in 2023 and 2028
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 111: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 112: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 113: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 114: Matrix on vendor position and classification
• 12.3 Amgen Inc.
• Exhibit 115: Amgen Inc. - Overview
• Exhibit 116: Amgen Inc. - Product / Service
• Exhibit 117: Amgen Inc. - Key offerings
• 12.4 AstraZeneca Plc
• Exhibit 118: AstraZeneca Plc - Overview
• Exhibit 119: AstraZeneca Plc - Product / Service
• Exhibit 120: AstraZeneca Plc - Key news
• Exhibit 121: AstraZeneca Plc - Key offerings
• 12.5 Bayer AG
• Exhibit 122: Bayer AG - Overview
• Exhibit 123: Bayer AG - Business segments
• Exhibit 124: Bayer AG - Key news
• Exhibit 125: Bayer AG - Key offerings
• Exhibit 126: Bayer AG - Segment focus
• 12.6 Boehringer Ingelheim International GmbH
• Exhibit 127: Boehringer Ingelheim International GmbH - Overview
• Exhibit 128: Boehringer Ingelheim International GmbH - Business segments
• Exhibit 129: Boehringer Ingelheim International GmbH - Key news
• Exhibit 130: Boehringer Ingelheim International GmbH - Key offerings
• Exhibit 131: Boehringer Ingelheim International GmbH - Segment focus
• 12.7 Dong A Socio Holdings Co. Ltd.
• Exhibit 132: Dong A Socio Holdings Co. Ltd. - Overview
• Exhibit 133: Dong A Socio Holdings Co. Ltd. - Product / Service
• Exhibit 134: Dong A Socio Holdings Co. Ltd. - Key offerings
• 12.8 Dr Reddys Laboratories Ltd.
• Exhibit 135: Dr Reddys Laboratories Ltd. - Overview
• Exhibit 136: Dr Reddys Laboratories Ltd. - Business segments
• Exhibit 137: Dr Reddys Laboratories Ltd. - Key offerings
• Exhibit 138: Dr Reddys Laboratories Ltd. - Segment focus
• 12.9 Eli Lilly and Co.
• Exhibit 139: Eli Lilly and Co. - Overview
• Exhibit 140: Eli Lilly and Co. - Product / Service
• Exhibit 141: Eli Lilly and Co. - Key news
• Exhibit 142: Eli Lilly and Co. - Key offerings
• 12.10 GlaxoSmithKline Plc
• Exhibit 143: GlaxoSmithKline Plc - Overview
• Exhibit 144: GlaxoSmithKline Plc - Business segments
• Exhibit 145: GlaxoSmithKline Plc - Key news
• Exhibit 146: GlaxoSmithKline Plc - Key offerings
• Exhibit 147: GlaxoSmithKline Plc - Segment focus
• 12.11 Pfizer Inc.
• Exhibit 148: Pfizer Inc. - Overview
• Exhibit 149: Pfizer Inc. - Product / Service
• Exhibit 150: Pfizer Inc. - Key news
• Exhibit 151: Pfizer Inc. - Key offerings
• 12.12 Sanofi SA
• Exhibit 152: Sanofi SA - Overview
• Exhibit 153: Sanofi SA - Business segments
• Exhibit 154: Sanofi SA - Key news
• Exhibit 155: Sanofi SA - Key offerings
• Exhibit 156: Sanofi SA - Segment focus
• 12.13 Sun Pharmaceutical Industries Ltd.
• Exhibit 157: Sun Pharmaceutical Industries Ltd. - Overview
• Exhibit 158: Sun Pharmaceutical Industries Ltd. - Product / Service
• Exhibit 159: Sun Pharmaceutical Industries Ltd. - Key offerings
• 12.14 Teva Pharmaceutical Industries Ltd.
• Exhibit 160: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 161: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 162: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 163: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 164: Teva Pharmaceutical Industries Ltd. - Segment focus
• 12.15 United Therapeutics Corp.
• Exhibit 165: United Therapeutics Corp. - Overview
• Exhibit 166: United Therapeutics Corp. - Product / Service
• Exhibit 167: United Therapeutics Corp. - Key offerings
• 12.16 Viatris Inc.
• Exhibit 168: Viatris Inc. - Overview
• Exhibit 169: Viatris Inc. - Business segments
• Exhibit 170: Viatris Inc. - Key news
• Exhibit 171: Viatris Inc. - Key offerings
• Exhibit 172: Viatris Inc. - Segment focus
• 12.17 Zydus Lifesciences Ltd.
• Exhibit 173: Zydus Lifesciences Ltd. - Overview
• Exhibit 174: Zydus Lifesciences Ltd. - Business segments
• Exhibit 175: Zydus Lifesciences Ltd. - Key offerings
• Exhibit 176: Zydus Lifesciences Ltd. - Segment focus

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 177: Inclusions checklist
• Exhibit 178: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 179: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 180: Research methodology
• Exhibit 181: Validation techniques employed for market sizing
• Exhibit 182: Information sources
• 13.5 List of abbreviations
• Exhibit 183: List of abbreviations